The emergence of dual-action receptor agonists in the management of type 2 diabetes and obesity has sparked considerable interest, particularly regarding retatrutide and tirzepatide. While both medications target both https://anyalklu104575.blogdal.com/39331111/retatrutide-vs-tirzepatide-a-comparative-analysis